Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;24(1):61-72.
doi: 10.1007/s11883-022-00985-0. Epub 2022 Jan 24.

Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions

Affiliations
Review

Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions

Michelle T Lee et al. Curr Atheroscler Rep. 2022 Jan.

Abstract

Purpose of review: This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions.

Recent findings: Assessed studies examine a remotely delivered hypertension and lipid program in 10,000 patients across a diverse healthcare network; a cluster-randomized trial of a village doctor-led intervention for hypertension control; empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); efficacy and safety of empagliflozin in hospitalized heart failure patients (EMPULSE); icosapent ethyl versus placebo in outpatients with coronavirus disease 2019 (PREPARE-IT 2); clinical safety, pharmacokinetics, and low-density lipoprotein cholesterol-lowering efficacy of MK-0161, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; and effects of aspirin on dementia and cognitive impairment in the ASCEND trial. Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.

Keywords: Aspirin; Atherosclerotic cardiovascular disease; Cardiovascular prevention; Empagliflozin; Heart failure.

PubMed Disclaimer

Conflict of interest statement

Michelle T. Lee, Jerin George, Hunaina Shahab, Melody Hermel, Jamal S. Rana: None.

Salim S. Virani: Honorarium, American College of Cardiology (Associate Editor for Innovations, acc.org).

References

    1. •• Anker SD, Butler J, Filippatos G et al. Empagliflozin in heart failure with a preservedejection fraction. N Engl J Med 2021; 385(16):1451–1461. (In a randomized trial of 5988 heart failure patients with left ventricular ejection fraction >40%, empagliflozin (compared with placebo) was associated with a significant risk reduction in the composite endpoint of cardiovascular death and first hospitalization for heart failure.) - PubMed
    1. Lee MT, Mahtta D, Dlouhy L, Shahab H, Al Rifai M, Virani SS. Highlights of cardiovascular disease studies presented at the 2021 European Society of Cardiology Congress. Curr Atheroscler Rep. 2021;23(12):76. doi: 10.1007/s11883-021-00975-8. - DOI - PubMed
    1. Hussain A, Al Rifai M, Mahtta D, Liu J, Jain V, Virani SS. Highlights from studies presented at the American Heart Association Scientific Sessions 2020: navigating new roads in prevention. Curr Atheroscler Rep. 2021;23(1):4. doi: 10.1007/s11883-020-00900-5. - DOI - PMC - PubMed
    1. Jain V, Al Rifai M, Mahtta D, Liu J, Hussain A, Virani SS. Highlights from studies presented at the virtual American College of Cardiology Scientific Sessions 2021: Staying updated with the latest advancements in prevention. Curr Atheroscler Rep. 2021;23(9):50. doi: 10.1007/s11883-021-00952-1. - DOI - PMC - PubMed
    1. Jia X, Lee MT, Ramsey DJ et al. Facility-level variation in reported statin-associated side effects among patients with atherosclerotic cardiovascular disease-perspective from the Veterans Affair healthcare system. Cardiovasc Drugs Ther 2021; Online ahead of print. - PubMed

Publication types

MeSH terms